Regeneron Pharmaceuticals (REGN) Stock Declines -15% Over 30 Days on Clinical Trial Setbacks
Key Takeaways
- REGN stock declined approximately 15% over the past 30 days amid disappointing clinical trial results for an experimental cancer drug and subsequent analyst downgrades.
- Over the past quarter, the stock fell about 19%, reflecting broader pressures from mixed first-quarter 2026 earnings and sector sentiment.
- Key drivers included a sharp sell-off following trial data releases and negative revisions to price targets.
- Positive developments, such as a $2.32 billion collaboration with Parabilis, provided limited offset to the negative momentum.
- Macroeconomic factors and biotech sector rotation contributed to sustained weakness.
- Investors should monitor upcoming pipeline updates and regulatory feedback for potential stabilization.
Regeneron Pharmaceuticals (REGN): Company Snapshot
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering, developing, and commercializing medicines for serious conditions in areas like eye health, inflammatory diseases, and oncology. Its approach relies heavily on proprietary antibody technologies and key partnerships, including the long-standing collaboration with Sanofi on products such as Dupixent. Operating in the competitive biopharmaceutical space, the company has built a solid base around established treatments like Eylea, yet recent pipeline challenges underscore the inherent risks that can quickly influence share prices.
REGN Stock Performance: Last 30 Days Compared to the Quarter
Over the last 30 days, REGN shares declined approximately 15%, moving from levels near $747 to a closing price of $638.88 on May 22, 2026. The path was largely trend-driven, with clear volatility tied to clinical news. Over the past quarter, the stock fell about 19%, dropping from around $771 to the recent close. This occurred along a fairly steady downward path, interrupted by earnings-related moves and wider sector pressures, keeping the shares range-bound inside an overall downtrend.
What Moved REGN in the Last 30 Days
The main catalyst was disappointing results from an experimental cancer drug trial. That news sparked an immediate 10.5% single-day drop and led to several analyst downgrades along with lower price targets. This company-specific event overshadowed a positive $2.32 billion collaboration announcement with Parabilis aimed at therapies for difficult-to-drug proteins. Investor focus shifted toward pipeline risks, while broader biotech sector rotation added to the downward pressure. No major macroeconomic changes directly hit the stock, but the trial outcome dominated trading and sustained selling pressure.
Quarterly Performance Influences on REGN
The wider quarterly decline reflected the combined impact of first-quarter 2026 earnings, which showed revenue growth of 19% to $3.6 billion but a 10% drop in GAAP net income. Industry developments in oncology and competitive positioning within biotech added caution. Macroeconomic factors, including interest-rate sensitivity for growth-oriented biotechs, weighed on valuations. Institutional selling and negative investor reaction after the clinical data release had the strongest cumulative effect, outweighing the positive collaboration news.
REGN Stock Forecast Drivers: What Comes Next
Investors should monitor upcoming clinical trial readouts, especially in oncology, along with any regulatory feedback on pipeline candidates. Industry trends in antibody-based therapies and potential new partnerships remain relevant. The broader macroeconomic environment, including interest rates and biotech funding conditions, could influence sentiment. Strategic items such as earnings guidance updates or competitive product launches also warrant attention, as do any shifts in analyst coverage.
Exploring AI Trading Bots for Portfolio Insights
When reviewing stocks like REGN, I sometimes look at Tickeron’s Trending AI Robots page to see how top-performing automated strategies are behaving across the market. It highlights a curated selection of the highest-ranked AI trading bots from the platform’s library, based on performance metrics, with transparent historical results and ongoing signals. Bots vary by strategy, timeframe, and risk parameters, which can help match different investor approaches. The page offers a straightforward way to review current options without needing to sift through hundreds of alternatives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Aroon Indicator for REGN shows an upward move is likely
REGN's Aroon Indicator triggered a bullish signal on August 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 247 similar instances where the Aroon Indicator showed a similar pattern. In of the 247 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on REGN as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on July 28, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
REGN broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.708) is normal, around the industry mean (20.145). P/E Ratio (20.639) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (1.377) is also within normal values, averaging (3.861). Dividend Yield (0.004) settles around the average of (0.018) among similar stocks. P/S Ratio (5.747) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement